MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader...
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma...
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and...
Debt-Free Balance Sheet With $21.6 Million in CashBROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the...
January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
Kuros Biosciences to provide investor updateat Octavian and Baader Bank Conferences Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences...
Consumer searches for supplement legitimacy increased 26% year-over-year as transparency becomes central purchasing criterion — industry analysis examines what drives...
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional...
– Collaboration is designed to improve analytical speed and accuracy of Freenome's blood-based cancer screening tests – BRISBANE, Calif., Jan. 12, 2026...
CONSHOHOCKEN, Pa., Jan. 12, 2026 /PRNewswire/ -- Suvoda, a clinical trial technology company, took decisive steps in 2025 toward a...
SAN ANTONIO, Jan. 12, 2026 /PRNewswire/ -- RealTime eClinical Solutions, a leader in clinical research software technology, today announced that...
Additional proof of concept data consistent and strengthen data set shared at ASH 2025Management to host meetings at JP Morgan...
Additional proof of concept data consistent and strengthen data set shared at ASH 2025Management to host meetings at JP Morgan...
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly...
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly...
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP...
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire /...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE...
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal...